Format

Send to

Choose Destination
Breast Cancer Res. 2011;13(6):221. doi: 10.1186/bcr2904. Epub 2011 Nov 30.

Luminal-B breast cancer and novel therapeutic targets.

Author information

1
Princess Margaret Hospital, 610 University Avenue, Toronto, Canada.

Abstract

Gene expression profiling has led to a new molecular classification of breast cancer characterized by four intrinsic subtypes: basal-like, HER2-positive, luminal A, and luminal B. Despite expressing estrogen receptor, the luminal-B subtype confers increased risk of early relapse with endocrine therapy compared with the luminal-A subtype. Although luminal-B definitions vary, the hallmark appears to be increased expression of proliferation-related genes. Several biological pathways are identified as possible contributors to the poor outcomes, and novel agents targeting these pathways are being developed with aims to improve survival. We review the definition of luminal-B breast cancer, its pathological and clinical features, and potential targets for treatment.

PMID:
22217398
PMCID:
PMC3326541
DOI:
10.1186/bcr2904
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center